Apyx Medical (NASDAQ:APYX) Stock Rating Upgraded by Zacks Research

Apyx Medical (NASDAQ:APYX) was upgraded by analysts at Zacks Research to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

Other analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Apyx Medical from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research note on Wednesday, June 24th. Finally, HC Wainwright started coverage on Apyx Medical in a report on Monday. They issued a “buy” rating and a $7.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Apyx Medical presently has a consensus rating of “Moderate Buy” and an average target price of $6.60.

Apyx Medical Stock Up 4.7%

Shares of NASDAQ APYX opened at $4.42 on Tuesday. The stock has a market capitalization of $185.25 million, a P/E ratio of -20.09 and a beta of 1.37. Apyx Medical has a one year low of $1.59 and a one year high of $5.08. The firm’s 50 day simple moving average is $4.22 and its two-hundred day simple moving average is $3.89. The company has a debt-to-equity ratio of 2.68, a current ratio of 5.80 and a quick ratio of 4.79.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.06. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%. The firm had revenue of $12.49 million during the quarter, compared to analyst estimates of $10.53 million. As a group, analysts expect that Apyx Medical will post -0.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new stake in Apyx Medical in the 3rd quarter worth approximately $28,000. Nwam LLC bought a new position in shares of Apyx Medical during the first quarter valued at approximately $47,000. Osaic Holdings Inc. bought a new position in shares of Apyx Medical during the second quarter valued at approximately $50,000. Franklin Resources Inc. purchased a new stake in Apyx Medical in the third quarter worth $59,000. Finally, Hudson Bay Capital Management LP purchased a new stake in Apyx Medical in the fourth quarter worth $73,000. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Trending Headlines about Apyx Medical

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Apyx Medical and set a $7.00 price target, implying meaningful upside from current levels.
• Positive Sentiment: The firm’s forecasts show gradually improving earnings over the next several quarters, with losses expected to narrow from around ($0.06) per share in mid-2026 to about ($0.03) per share by Q4 2027.
• Neutral Sentiment: HC Wainwright’s full-year estimates still call for losses in FY2026 and FY2027, so the business has not yet been projected to turn profitable. Apyx Medical stock page

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.